This page is part of the HL7 FHIR Implementation Guide: minimal Common Oncology Data Elements (mCODE) Release 1 - US Realm | STU1 (v1.16.0: STU 2 Ballot 1) based on FHIR R4. The current version which supercedes this version is 2.0.0. For a full list of available versions, see the Directory of published versions
Generated Narrative
status: completed
category: Outpatient
medication: doxorubicin hydrochloride 20 MG per 10 ML Injection
effective: 2018-04-22
- | Actor |
* | Generated Summary: id: 55667788; Nancy Nurse ; gender: female |
reasonReference: Generated Summary: Remission; Confirmed; Problem List Item; Primary malignant neoplasm of female left breast (disorder); onset: 2018-03-16
request: Generated Summary: status: active; intent: order; Outpatient; DOXOrubicin; authoredOn: 2018-04-12
note: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/us-core-practitioner-nancy-oncology-nurse @2018-04-22)
- | Route | Dose |
* | Intravenous route (qualifier value) | 105.96 mg |